On a disclosed basis, revenue fell 13.1% year on year, from KRW 16.2 billion in 2024 to KRW 14.1 billion in 2025. The company attributed the decline to its response to supply-chain adjustments.
The operating loss widened from KRW 275 million in 2024 to KRW 2.4 billion in 2025, and the operating margin moved from -1.7% to -17.0%. The company has posted losses for two consecutive years, from 2024 through 2025.
The net loss attributable to controlling shareholders widened from KRW 54.78 million in 2024 to KRW 8.03 billion in 2025, and the total net loss was the same KRW 8.03 billion. The net loss is far larger than the operating loss, which is a notable feature of the 2025 results.
Press coverage pointed to R&D spending as a factor behind the operating loss. Operating cash flow swung from KRW 1.66 billion in 2024 to -KRW 1.53 billion in 2025, moving from cash generation to cash outflow. The balance sheet has changed, however.
Press reports say the company was in full capital impairment at the end of 2024, and that total equity recovered to KRW 7.97 billion at the end of 2025 after preferred shares converted into common stock and a rights offering.
Total liabilities at the end of 2025 were KRW 6.06 billion, and the debt ratio moved from -545.2% in 2024, reflecting negative equity, to 76.0% in 2025.
On a quarterly basis, the third quarter of 2026 showed revenue of KRW 4.55 billion, an operating loss of KRW 497 million and a net loss attributable to controlling shareholders of KRW 1 billion.
The cumulative net loss attributable to controlling shareholders over the last four quarters (first quarter to fourth quarter of 2025) totaled KRW 8.03 billion. Press reports say monthly operating profit turned positive from May 2026, but the operating loss continued through the third quarter of 2026.